GSK5458514

GSK5458514 is a **prostate-specific membrane antigen (PSMA) targeting T cell engager** in clinical development for the treatment of **metastatic castration-resistant prostate cancer (mCRPC)**. This investigational drug is designed to recruit and activate T cells, specifically directing them to PSMA-expressing prostate cancer cells, thereby promoting targeted cell death. GSK5458514 is being developed by GSK and is currently the subject of an ongoing Phase 1/2 clinical trial evaluating its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, both as a monotherapy and in combination with other anticancer agents in adults with prostate cancer[1][2][3][4][5][6][7].